163
Participants
Start Date
August 31, 2015
Primary Completion Date
April 30, 2016
Study Completion Date
May 31, 2016
HLD200 methylphenidate hydrochloride (MPH) Capsules
HLD200 Doses: 40, 60 or 80 mg
Placebo
Duke University Medical Center, Duke Child and Family Study Center, Durham
Clinical Neuroscience Solutions, Inc, Jacksonville
Sarkis Clinical Trials, Gainesville
Florida Clinical Research Center, LLC, Maitland
Medical Research Group of Central Florida, Orange City
Children's Developmental Center, P.A., Winter Park
Clinical Neuroscience Solutions, Inc., Orlando
QPS MRA, dba Miami Research Associates, LLC, South Miami
Scientific Clinical Research, Inc., North Miami
Florida Clinical Research Center, LLC, Bradenton
Clinical Neuroscience Solutions, Inc., Memphis
Pedia Research, LLC, Owensboro
IPS Research Company, Oklahoma City
Cutting Edge Research Group, Oklahoma City
Bayou City Research, Ltd, Houston
Red Oak Psychiatry Associates, PA, Houston
University of Texas Health Science Center at San Antonio, San Antonio
Westex Clinical Investigations, Lubbock
Ericksen Research and Development, Clinton
AVIDA, Newport Beach
Seattle Children's Hospital, Seattle
Lead Sponsor
Ironshore Pharmaceuticals and Development, Inc
OTHER